Revenue
No reported data
Jasper Therapeutics, Inc. (JSPR)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $63.1M | $55.8M | $51.8M | $842,000 | $139,000 | $177,000 |
| Operating expenses | $83.9M | $76.2M | $68.9M | $51.2M | $36.8M | $20.7M |
| Operating income | −$83.9M | −$76.2M | −$68.9M | −$51.2M | −$36.8M | −$20.7M |
| EBITDAderived | −$82.8M | −$74.9M | −$67.8M | −$50.2M | −$36.5M | — |
| Net income | −$75.8M | −$71.3M | −$64.5M | −$37.7M | −$30.6M | −$31.7M |
| Basic EPSper diluted share | -$3.95 | -$4.89 | -$6.18 | -$10.33 | -$2.69 | -$5.17 |
| Diluted EPSper diluted share | -$3.95 | -$4.89 | -$6.18 | -$10.33 | -$2.69 | -$5.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 22, 2025Form 4 | WIGGANS THOMAS GDirector | BuyVoting Common Stock · indirect | 41.0K | $2.43 | $99.6K | 41.0K |
| Sep 22, 2025Form 4 | WIGGANS THOMAS GDirector | BuyCommon Stock Warrant (right to buy) · derivative · indirect | 41.0K | — | — | 41.0K |
| Sep 22, 2025Form 4 | Lucas SvetlanaDirector | BuyVoting Common Stock | 20.0K | $2.43 | $48.6K | 20.0K |
| Sep 22, 2025Form 4 | Lucas SvetlanaDirector | BuyCommon Stock Warrant (right to buy) · derivative | 20.0K | — | — | 20.0K |
| Sep 22, 2025Form 4 | MARTELL RONPresident and CEO | BuyVoting Common Stock | 41.0K | $2.43 | $99.6K | 74.1K |